+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Therapeutics Market - Global Forecast 2026-2032- Product Image
mRNA Therapeutics Market - Global Forecast 2026-2032- Product Image
New

mRNA Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 190 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666329
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The mRNA therapeutics market is undergoing rapid transformation, fueled by scientific innovation, evolving regulatory frameworks, and dynamic shifts in global supply chains. Senior leaders must navigate emerging complexities and seize opportunities shaped by advances in genetic medicine, operational scale-up, and policy changes.

Market Snapshot: mRNA Therapeutics Market Growth

The mRNA therapeutics market grew from USD 11.33 billion in 2025 to USD 12.58 billion in 2026, with a projected CAGR of 13.23% reaching USD 27.05 billion by 2032. This robust growth illustrates expanding adoption and maturation of mRNA-based therapies across multiple clinical and commercial applications.

Scope & Segmentation

This report covers the full value chain and competitive environment driving mRNA therapeutics, offering granular insights across the following dimensions:

  • Technology Platforms: Lipid nanoparticle-based systems, polymer constructs, and viral vectors—each with distinct advantages in delivery precision, dosing, and tissue targeting.
  • Therapeutic Applications: Cardiovascular and rare diseases, infectious disease vaccines, and oncology; considerations for both chronic and acute settings.
  • Administration Routes: Intramuscular, intravenous, and subcutaneous delivery routes, each aligning with specific therapeutic strategies and patient needs.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific, reflecting clinical trial design, regulatory context, talent pools, and supply chain infrastructures.
  • Operational Segments: Sourcing, manufacturing footprints, and end-to-end supply chain strategies as influenced by shifting trade and regulatory demands.

Key Takeaways: Strategic Insights for Decision Makers

  • Scientific progress in payload engineering and delivery technologies is expanding the utility of mRNA beyond traditional vaccine applications—enabling targeting of complex disease pathways and longer-lasting therapeutic effects.
  • Interdisciplinary collaboration is streamlining clinical candidate development and elevating safety and efficacy profiles, vital for expanding clinical adoption and regulatory acceptance.
  • Regulators are adapting approval pathways for nucleic acid therapeutics, emphasizing interoperable evidence, robust comparability, and closer post-market monitoring—this demands agile development and manufacturing integration.
  • Strategic alliances, both cross-sector and within biopharma, are accelerating innovation and market entry, particularly for niche indications and platform advancements.
  • Supplier resilience, transparent sourcing, and proactive risk assessment are now mission-critical, as the market responds to policy shifts and heightened focus on raw material security.

Tariff Impact: Operational Adjustment in the U.S. Ecosystem

Recent U.S. tariff adjustments have created new variables for sourcing and procurement teams, especially concerning critical raw materials and specialized components. These changes are prompting organizations to review supplier diversification, regional alternatives, and contingency planning. Strategic decisions now balance direct costs with continuity of supply and compliance. Contract manufacturers are increasing transparency around source and regulatory documentation to maintain uninterrupted clinical and commercial development.

Methodology & Data Sources

This analysis integrates rigorous qualitative and quantitative methods, including structured stakeholder interviews, in-depth literature reviews, and technical assessment of assay requirements. All findings were cross-validated with published regulatory documents and expert peer review to ensure reliability and practical relevance.

Why This Report Matters

  • Enables strategic planning with deep segmentation insights linking platform type, application, and manufacturing needs to investment priorities and partnership models.
  • Equips leaders to navigate regulatory evolution, supplier qualification, and regional differences, supporting resilient supply and accelerated technology translation.

Conclusion

Sustainable success in mRNA therapeutics will rely on scientific leadership, strategic alliances, integrated supply chains, and proactive regulatory alignment. This report offers the clarity and depth needed to inform resilient, forward-looking decisions in the evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. mRNA Therapeutics Market, by Technology Platform
8.1. Lipid Nanoparticles
8.2. Polymer Based
8.3. Viral Vectors
9. mRNA Therapeutics Market, by Delivery Method
9.1. Intramuscular
9.2. Intravenous
9.3. Subcutaneous
10. mRNA Therapeutics Market, by Therapeutic Application
10.1. Cardiovascular
10.2. Infectious Diseases
10.3. Oncology
10.4. Rare Diseases
11. mRNA Therapeutics Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. mRNA Therapeutics Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. mRNA Therapeutics Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States mRNA Therapeutics Market
15. China mRNA Therapeutics Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. Altamira Therapeutics, Inc.
16.6. Arcturus Therapeutics Holdings, Inc.
16.7. AstraZeneca plcEthris GmbH
16.8. BioNTech SE
16.9. Chimeron Bio, Inc.
16.10. CureVac N.V.
16.11. eTheRNA Immunotherapies N.V.
16.12. Genevant Sciences Corporation
16.13. GlaxoSmithKline plc
16.14. Gritstone Bio, Inc.
16.15. Immorna Biotherapeutics, Inc.
16.16. Kernel Biologics, Inc.
16.17. Lonza Group Ltd.
16.18. Merck & Co., Inc.
16.19. Moderna, Inc.
16.20. MycoTechnology, Inc.
16.21. NobleGen, Inc.
16.22. Novartis AG
16.23. Nutcracker Therapeutics, Inc.
16.24. Pfizer Inc.
16.25. Sanofi S.A.
16.26. Strand Therapeutics, Inc.
16.27. Tiba Biotech, LLC
16.28. VaxEquity Ltd.
List of Figures
FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 37. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 38. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 39. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 40. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 42. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 43. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 44. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 46. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 47. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 52. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 54. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 55. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 56. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 58. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 59. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 60. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 62. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 63. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 71. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 72. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 73. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 75. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 76. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 77. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 79. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 80. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 81. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 83. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 84. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 85. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 87. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 88. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 89. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 91. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 92. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 95. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 96. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 97. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 98. CHINA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 99. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
TABLE 100. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
TABLE 101. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this mRNA Therapeutics market report include:
  • Altamira Therapeutics, Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • AstraZeneca plcEthris GmbH
  • BioNTech SE
  • Chimeron Bio, Inc.
  • CureVac N.V.
  • eTheRNA Immunotherapies N.V.
  • Genevant Sciences Corporation
  • GlaxoSmithKline plc
  • Gritstone Bio, Inc.
  • Immorna Biotherapeutics, Inc.
  • Kernel Biologics, Inc.
  • Lonza Group Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • MycoTechnology, Inc.
  • NobleGen, Inc.
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Strand Therapeutics, Inc.
  • Tiba Biotech, LLC
  • VaxEquity Ltd.

Table Information

Report AttributeDetails
No. of Pages190
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 12.58 Billion
Forecasted Market Value ( USD ) by 2032 $ 27.05 Billion
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Indication (Metabolic & Genetic Diseases), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Indication (Metabolic & Genetic Diseases), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 170 Pages
  • Global
From
mRNA Therapeutics CDMO Market Report 2025 - Product Image

mRNA Therapeutics CDMO Market Report 2025

  • Report
  • 250 Pages
  • Global
From
mRNA Therapeutics - Global Strategic Business Report - Product Image

mRNA Therapeutics - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
MRNA Therapeutics Contract Development Manufacturing Organization Market - Product Image

MRNA Therapeutics Contract Development Manufacturing Organization Market

  • Report
  • 88 Pages
  • Global
From
mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report - Product Image

mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report

  • Report
  • 166 Pages
  • Global
From

About the mRNA Therapeutics Market

The mRNA Therapeutics market is a subset of the larger Genomics market, which focuses on the development of therapeutics based on messenger RNA (mRNA). mRNA is a type of genetic material that is used to produce proteins in cells. mRNA Therapeutics are designed to target specific diseases by delivering mRNA molecules to cells, which can then be used to produce proteins that can treat or prevent the disease. mRNA Therapeutics have the potential to revolutionize the way diseases are treated, as they can be used to target specific diseases without affecting other parts of the body. The mRNA Therapeutics market is still in its early stages, but is expected to grow rapidly in the coming years. Companies in the market are focused on developing mRNA-based therapeutics for a variety of diseases, including cancer, cardiovascular diseases, and neurological disorders. Some of the companies in the mRNA Therapeutics market include Moderna, CureVac, Arcturus Therapeutics, and BioNTech. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.